Harvard’s Wyss Institute is leveraging its unique technology innovation capabilities to develop diagnostic, therapeutic, and vaccine interventions for COVID-19 at lightning speed.
Browsing: Clinical > Vaccines
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
A COVID-19 vaccine is widely regarded as the panacea for a fast track to normal life. There are currently over 120 vaccine candidates in development, with ten already in clinical trials. Take a look at the front-runners.
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
The first human trial testing a potential COVID-19 vaccine has been successful, with initial results suggesting the vaccine is safe and capable of generating an immune response against SARS-CoV-2 in humans.
Researchers have demonstrated that two COVID-19 vaccine candidates can protect against COVID-19 in primates, with re-exposure triggering an immune response in rhesus macaques.
Researchers at the Korea Institute of Science and Technology (KIST) and Catholic University of Korea (CUK) have developed a vaccine platform against MERS coronavirus (MERS-CoV) that could be used to develop a vaccine for COVID-19.